Skip to content
The Nexus
DossierENTITY

biotech deals

Coverage of biotech deals in the Nexus archive.

Earliest in view: Jun 21 · 01:30 UTCMost recent: Jul 21 · 04:00 UTC
Co-mentioned in this coverage
Big Pharmaorganization1Patents expiring on lucrative drugstopic1drugmakersorganization1Blockbuster medicinestopic1Diederik Stadigperson1ING Researchorganization1United Statesplace1Chinaplace1investment linkstopic1geopolitical scrutinytopic1
Recent coverage
  • BUSINESSJul 21 · 04:00 UTCFINANCIAL TIMES WORLD
    Biotech deals surge to record as fear of missing out grips Big Pharma

    Biotech deals have surged to a record high as Big Pharma experiences fear of missing out, driven by the impending expiration of patents on profitable drugs, prompting pharmaceutical companies to seek new blockbuster medicines.

  • BUSINESSJun 21 · 01:30 UTCSCMP CHINA
    Cross-border biotech deals grow more complex as US targets China investment links

    Cross-border biotech deals between China and the United States are becoming more complex due to increased U.S. efforts to restrict investment and technology transfers, with analysts predicting a modest slowdown. Geopolitical scrutiny is expected to lead to fewer deals, according to ING Research's Diederik Stadig.